Should you buy NeoGenomics (NEO)?
Updated
NeoGenomics is an oncology diagnostics company trading at a compelling 18% potential upside relative to analyst price targets, but weak quality metrics and an unfavorable risk/reward profile at current levels make the investment speculative until margin improvement materializes.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
NeoGenomics generates positive free cash flow with a Piotroski F-Score of 8 out of 9, signaling strong balance-sheet health even amid thin margins, and analysts see roughly 36% upside to their consensus target. Quality breakdown | Free cash flow margin improves above 6% and revenue growth accelerates above 10% over the next 12 months. | →Stable |
| CounterOperating and net margins are near zero, and FCF yield of 2.3% is too thin to support meaningful reinvestment or shareholder returns. | ||
NeoGenomics has beaten or matched earnings estimates in each of the last three reported quarters, with an average surprise of over 200%, suggesting consistent execution versus investor expectations. Earnings | The company continues to meet or beat consensus EPS in the next two quarterly reporting periods. | →Stable |
| CounterThe outsized average surprise is distorted by a single 800% beat, and underlying beat consistency is not established over a long track record. | ||
With a PEG ratio of 0.21 and a forward P/E of 30x, NeoGenomics is priced at a moderate premium to growth that appears justified if earnings continue to expand, making it attractively valued relative to its growth trajectory. Valuation breakdown | Earnings growth sustains above 20% annually so the PEG ratio remains below 0.5 over the next year. | →Stable |
| CounterA forward P/E of 30x is expensive in absolute terms for a company with near-zero operating margins and a sub-$2B market cap. | ||
NeoGenomics generates positive free cash flow with a Piotroski F-Score of 8 out of 9, signaling strong balance-sheet health even amid thin margins, and analysts see roughly 36% upside to their consensus target.
→Stable- Expectation
- Free cash flow margin improves above 6% and revenue growth accelerates above 10% over the next 12 months.
CounterOperating and net margins are near zero, and FCF yield of 2.3% is too thin to support meaningful reinvestment or shareholder returns.
NeoGenomics has beaten or matched earnings estimates in each of the last three reported quarters, with an average surprise of over 200%, suggesting consistent execution versus investor expectations.
→Stable- Expectation
- The company continues to meet or beat consensus EPS in the next two quarterly reporting periods.
CounterThe outsized average surprise is distorted by a single 800% beat, and underlying beat consistency is not established over a long track record.
With a PEG ratio of 0.21 and a forward P/E of 30x, NeoGenomics is priced at a moderate premium to growth that appears justified if earnings continue to expand, making it attractively valued relative to its growth trajectory.
→Stable- Expectation
- Earnings growth sustains above 20% annually so the PEG ratio remains below 0.5 over the next year.
CounterA forward P/E of 30x is expensive in absolute terms for a company with near-zero operating margins and a sub-$2B market cap.
▸ Show 1 more pillar▾ Show fewer
The stock's current risk/reward setup shows only 18% upside against 15% downside, and the momentum score of 4.6 is barely above the minimum threshold, limiting near-term entry conviction.
→Stable- Expectation
- Price momentum score rises above 5.5 and the asymmetry ratio climbs above 1.5 within 12 months as earnings improve.
CounterRSI at 70 signals near-term overbought conditions, and falling on-balance volume indicates distribution rather than accumulation.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1NeoGenomics generates positive free cash flow with a Piotroski F-Score of 8 out of 9, signaling strong balance-sheet health even amid thin margins, and analysts see roughly 36% upside to their consensus target.
Trip ifFree cash flow margin falls below 2% for 2 consecutive quarters.
- P2NeoGenomics has beaten or matched earnings estimates in each of the last three reported quarters, with an average surprise of over 200%, suggesting consistent execution versus investor expectations.
Trip ifEPS surprise falls below 0% in at least 2 of the next 3 quarters.
- P3With a PEG ratio of 0.21 and a forward P/E of 30x, NeoGenomics is priced at a moderate premium to growth that appears justified if earnings continue to expand, making it attractively valued relative to its growth trajectory.
Trip ifForward P/E rises above 40x without a corresponding increase in earnings growth above 30%.
- P4The stock's current risk/reward setup shows only 18% upside against 15% downside, and the momentum score of 4.6 is barely above the minimum threshold, limiting near-term entry conviction.
Trip ifPrice drops below $10.31 stop-loss level or RSI rises above 80 without subsequent pullback.
How the engine reached this verdict
TrendMatrix's engine output for NeoGenomics, Inc. (NEO) is SELL_IF_HOLDING with medium conviction, score 5.7/10 at $13.39. An L1 hard-floor gate blocked the positive-verdict path — Quality below minimum threshold. Co-failing gates ( ASYMMETRY:-0.2=NEGATIVE) reinforce the read; dimensional pillars cannot lift the engine output above the verdict floor while the L1 gate is active.
The engine's exit framework anchors to a tactical sell band near $13.39, with structural invalidation at $12.52. The asymmetric R:R against a reversal hypothesis is -0.19 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bear side: V8: Target reached (-2.7% upside); Quality below floor (3.5 < 4.0); Value-trap signals (2/5): High leverage (D/E 3.6), Material insider selling (3 sells, 0.09% of cap). Active engine warnings: V8: Target reached (-2.7% upside), Quality below floor (3.5 < 4.0), Value-trap signals (2/5): High leverage (D/E 3.6), Material insider selling (3 sells, 0.09% of cap).
The dominant failed gate is reward-to-risk (NEGATIVE). SELL flips back toward HOLD if reward-to-risk recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:6.8>=5.5.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates NEO — 10-dimension breakdown →
Bear case
- ▸V8: Target reached (-2.7% upside)
- ▸Quality below floor (3.5 < 4.0)
- ▸Value-trap signals (2/5): High leverage (D/E 3.6), Material insider selling (3 sells, 0.09% of cap)